| 112.94 -4.565 (-3.88%) | 09-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 139.59 |
1-year : | 147.61 |
| Resists | First : | 119.51 |
Second : | 126.37 |
| Pivot price | 113.06 |
|||
| Supports | First : | 108.41 |
Second : | 90.19 |
| MAs | MA(5) : | 113.87  |
MA(20) : | 113.66 |
| MA(100) : | 91.17 |
MA(250) : | 70.75 |
|
| MACD | MACD : | 0.8 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 52.5 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 126.37 | Low : | 28.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CORT ] has closed above bottom band by 48.4%. Bollinger Bands are 56.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 118.93 - 119.56 | 119.56 - 120.09 |
| Low: | 110.61 - 111.3 | 111.3 - 111.88 |
| Close: | 111.81 - 112.98 | 112.98 - 113.97 |
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Wed, 23 Sep 2026
Corcept names Justin Gunn to lead endocrinology division - Investing.com
Wed, 23 Sep 2026
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant - TradingView
Wed, 23 Sep 2026
Corcept Announces Planned Leadership Transition - Yahoo Finance
Tue, 22 Sep 2026
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus - Yahoo Finance
Mon, 21 Sep 2026
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer - Your Wyoming Link
Mon, 21 Sep 2026
Corcept Therapeutics (CORT) Stock Analysis: A Promising Biotech with 27.84% Upside Potential - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 108 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 76.9 (%) |
| Shares Short | 9,700 (K) |
| Shares Short P.Month | 9,440 (K) |
| EPS | 0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.53 |
| Profit Margin | 6.6 % |
| Operating Margin | 16.1 % |
| Return on Assets (ttm) | 0.4 % |
| Return on Equity (ttm) | 8.2 % |
| Qtrly Rev. Growth | 31.7 % |
| Gross Profit (p.s.) | 7.55 |
| Sales Per Share | 7.68 |
| EBITDA (p.s.) | 0.07 |
| Qtrly Earnings Growth | 24.1 % |
| Operating Cash Flow | 110 (M) |
| Levered Free Cash Flow | 77 (M) |
| PE Ratio | 250.97 |
| PEG Ratio | 0.8 |
| Price to Book value | 17.26 |
| Price to Sales | 14.69 |
| Price to Cash Flow | 111.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|